Emiliano Cappello

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 8

Top Topics

Coronavirus Disease

Mesenchymal Stem Cells

Top Venues

Expert opinion on drug discovery

This page only lists publications with an associated author ORCID identifier.

Publications

Irma Convertino, Sara Ferraro, Emiliano Cappello, Giulia Valdiserra, Marco Bonaso, Marco Tuccori
Tixagevimab + cilgavimab against SARS-CoV-2: the preclinical and clinical development and real-world evidence. Expert opinion on drug discovery 18 (3) (2023)
Irma Convertino, Sara Ferraro, Emiliano Cappello, Giulia Valdiserra, Marco Bonaso, Marco Tuccori
Tixagevimab + cilgavimab against SARS-CoV-2: the preclinical and clinical development and real-world evidence. Expert opinion on drug discovery 18 (3) (2023)
Irma Convertino, Sara Ferraro, Emiliano Cappello, Giulia Valdiserra, Marco Bonaso, Marco Tuccori
Tixagevimab + cilgavimab against SARS-CoV-2: the preclinical and clinical development and real-world evidence. Expert opinion on drug discovery 18 (3) (2023)
Irma Convertino, Sara Ferraro, Emiliano Cappello, Giulia Valdiserra, Marco Bonaso, Marco Tuccori
Tixagevimab + cilgavimab against SARS-CoV-2: the preclinical and clinical development and real-world evidence. Expert opinion on drug discovery (2023)
Irma Convertino, Sara Ferraro, Emiliano Cappello, Giulia Valdiserra, Marco Bonaso, Marco Tuccori
Tixagevimab + cilgavimab against SARS-CoV-2: the preclinical and clinical development and real-world evidence. Expert opinion on drug discovery (2023)
Marco Tuccori, Irma Convertino, Sara Ferraro, Emiliano Cappello, Giulia Valdiserra, Giulia de Luca, Massimo Franchini, Daniele Focosi
Preclinical discovery and development of the casirivimab + imdevimab cocktail for the treatment of novel coronavirus infection: the rise and fall. Expert opinion on drug discovery 17 (6) (2022)
Marco Tuccori, Irma Convertino, Sara Ferraro, Giulia Valdiserra, Emiliano Cappello, Elisabetta Fini, Daniele Focosi
An overview of the preclinical discovery and development of bamlanivimab for the treatment of novel coronavirus infection (COVID-19): reasons for limited clinical use and lessons for the future. Expert opinion on drug discovery 16 (12) (2021)
Marco Tuccori, Sara Ferraro, Irma Convertino, Emiliano Cappello, Giulia Valdiserra, Corrado Blandizzi, Fabrizio Maggi, Daniele Focosi
Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline. mAbs 12 (1) (2020)